ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Pinoresinol Diglucoside Attenuates Nuclear Receptor Coactivator 4-Mediated Ferritinophagy Associated with Cisplatin-Induced Hearing Loss.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Functionalized Biomimetic Scaffolds for Human-Derived Auditory Neural Circuit Construction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Restoring Iron Homeostasis via Smoothened Inhibition: A Novel Strategy Against Hearing Loss.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Pinoresinol Diglucoside Attenuates Nuclear Receptor Coactivator 4-Mediated Ferritinophagy Associated with Cisplatin-Induced Hearing Loss.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Cisplatin can cause irreversible hearing loss. However, effective approaches to its prevention are not established. In this study, the effect of the traditional Chinese medicine monomer pinoresinol diglucoside (PDG) is evaluated on cisplatin-induced ototoxicity and its underlying mechanism of action. PDG significantly increases cell viability and inhibits reactive oxygen species production and ferroptosis in cisplatin-treated House Ear Institute-Organ of Corti 1 cells and basilar membranes. PDG partially restores hearing loss caused by cisplatin. Transcriptome sequencing identifies Suppressor of Cytokine Signaling 1 (SOCS1), which is significantly elevated in the cisplatin-only group but significantly reduced after PDG application. SOCS1 is a ferroptosis-promoting factor, and knocking it down significantly inhibits nuclear receptor coactivator 4 (NCOA4) and inhibits ferritinophagy. Transmission electron microscopy reveals that knocking down SOCS1 reduces the number of autophagic lysosomes induced by cisplatin. Co-immunoprecipitation is performed to confirm the interaction between SOCS1 and NCOA4. Taken together, these results indicate that PDG inhibits NCOA4-mediated ferritinophagy by downregulating SOCS1, which reduces cisplatin-induced ototoxicity. This study provides a new clinical option for the prevention of cisplatin-induced hearing loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.